Study Details | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | ClinicalTrials.gov. This evidence concerns the gene ERBB2 and breast carcinoma.